Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Blix

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Acta Oncologica (Stockholm, Sweden)|February 10, 2026
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trialKathinka Schmidt Slørdahl, Katarina Puco, Ragnhild Sørum Falk, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 14, 2026
Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1Kristine Wiborg Høgsbjerg, Mette Skovhus Thomsen, Else Maae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2020
Olaparib monotherapy as primary treatment in unselected triple negative breast cancerH P Eikesdal, S Yndestad, A Elzawahry, et al.
JCO Precision Oncology|December 1, 2023
Homologous Recombination Deficiency Across Subtypes of Primary Breast CancerSynnøve Yndestad, Christina Engebrethsen, Andrea Herencia-Ropero, et al.
Nature Medicine|May 5, 2022
A national precision cancer medicine implementation initiative for NorwayKjetil Taskén, Hege E G Russnes, Eline Aas, et al.
Clinical Breast Cancer|May 10, 2025
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal PerspectivesLars Asphaug, Lars A Akslen, Egil S Blix, et al.
ESMO Open|June 5, 2024
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)H O Ohnstad, E S Blix, L A Akslen, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Acta Oncologica (Stockholm, Sweden)|February 10, 2026
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trialKathinka Schmidt Slørdahl, Katarina Puco, Ragnhild Sørum Falk, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 14, 2026
Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1Kristine Wiborg Høgsbjerg, Mette Skovhus Thomsen, Else Maae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2020
Olaparib monotherapy as primary treatment in unselected triple negative breast cancerH P Eikesdal, S Yndestad, A Elzawahry, et al.
JCO Precision Oncology|December 1, 2023
Homologous Recombination Deficiency Across Subtypes of Primary Breast CancerSynnøve Yndestad, Christina Engebrethsen, Andrea Herencia-Ropero, et al.
Nature Medicine|May 5, 2022
A national precision cancer medicine implementation initiative for NorwayKjetil Taskén, Hege E G Russnes, Eline Aas, et al.
Clinical Breast Cancer|May 10, 2025
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal PerspectivesLars Asphaug, Lars A Akslen, Egil S Blix, et al.
ESMO Open|June 5, 2024
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)H O Ohnstad, E S Blix, L A Akslen, et al.
Pageof 15